Exelixis (EXEL) – Corporate News
-
Exelixis (EXEL) Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial of Cabozantinib in Combination with Atezolizumab
-
Bristol-Myers Squibb (BMY) and Exelixis (EXEL) Announce Opdivo with CABOMETYX Demonstrated Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to EXEL Stock Lookup